Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.

1
2nd Call in HEALTH in FP7 Astrid
Hoebertz European and International
Programmes FFG Austrian Research Promotion
Agency
2
7th Framework Programme (FP7) 2007 - 2013
COOPERATION Collaborative research Predefined
themes, refined instruments
IDEAS Frontier Research Individual grants,
European Research Council
PEOPLE Human Potential Mobility of Researchers
CAPACITIES Research Capacity Infrastructure,
SMEs, science society,
Joint Research Center non-nuclear

EURATOM
3
COOPERATION Collaborative research Predefined
themes, refined instruments

• HEALTH 6.1 Billion
• Food, Agriculture and Fisheries, and
  Biotechnology 1.9
• Information and Communication Technologies 9.1
• Nanosciences, Nanotechnologies, Materials and new
  production technologies
• 3.5
• Energy 2.3
• Environment (including Climate Change) 1.9
• Transport (including Aeronautics) 4.2
• Socio-economic Sciences and the Humanities 0.6
• Space 1.4
• Security 1.4
• Total 32.4 Billion Euro!

4
Theme 1- HEALTH 6.1 Billion for 7 years

• Aims
• Improving Health of European Citizens
• Strengthening European Health Industry
• Global Health Issues, e.g Epidemics
• Focus
• Translational Research (basic research ? clinical
  application)
• New therapies (Development and Validation)
• Diagnostic Instruments, medical technologies
• Efficient Health Systems
• gt In the Health theme, the Framework programme
  supports basic and applied collaborative
  research this includes discovery activities,
  translational research and early clinical trials
  (normally only phase I and II)

5
Cross-cutting aspects for HEALTH in FP7

• Special emphasis and measures for
• SMEs
• Participation encouraged in all areas
• Special topics for SMEs
• Support actions
• gt Out of the 6 billion dedicated to HEALTH the
  share going to SMEs is expected to be at least
  15 or 900 million.

6
Cross-cutting aspects for HEALTH in FP7

• Special emphasis and measures for
• International Cooperation
• Participation possible in all areas
• Funding will be provided to participants from
  International Co-operation partner countries
  (ICPC)
• Specific International Cooperation Actions
  (SICA) aim to generate, share and use knowledge
  through partnership with third countries in areas
  identified through bi-regional dialogues with
  third countries/regions of mutual interest and
  benefit
• one group of ICPC Western Balkan Countries
  (Albania, Bosnia-Herzegovina, Kosovo, Montenegro)

7
Theme 1- HEALTH

• for 2007-2008 (year 1 2 of FP7)
• Call A - first deadline 19 April 2007 637
  million (closed by now - published topics on
  the web)
• Call B - second deadline 18 September 2007
  549 million (official publication foreseen
  for 18th June)
• - Topics get published in Work programmes
• - for each topic funding scheme/project type is
  pre-specified

8
HEALTH Funding Schemes Project types

• Collaborative projects
• research projects carried out by consortia with
  participants from different countries
• aiming at developing new knowledge, new
  technology, products, demonstration activities or
  common resources for research
• the size, scope and internal organisation of
  projects can vary from field to field and from
  topic to topic
• projects can range from small or medium-scale
  focused research actions to largescale
  integrating projects for achieving a defined
  objective. Projects can also target special
  groups such as SMEs.
• Coordination and support actions
• activities aimed at coordinating or supporting
  research activities and policies (networking,
  exchanges, trans-national access to research
  infrastructures, studies, conferences, etc.)

9
Consortia composition

• Member States EU 27
• Associated Countries
• Iceland, Liechtenstein, Norway
• Switzerland, Israel
• Turkey, Croatia, Serbia, Macedonia (FYROM)
• International Cooperation Partner Countries
  (ICPC)
• ACP Countries (African, Carribean, Pacific)
• Asia
• EECA (Eastern Europe and Central Asia)
• Latin America
• MPC (Mediterranean Partner Countries)
• WBC (Western Balkan Countries)

10
Consortia composition

• Collaborative Projects
• At least three legal entities (defined as
  organisations or individual researchers as above)
  must participate, each of which is established in
  a Member State or Associated country, and no two
  of which are established in the same Member State
  or Associated country. All three legal entities
  must be independent of each other, meaning they
  are not subsidiaries of the same organisation or
  of each other.
• 2. SICA projects
• At least four legal entities must participate,
  of which at least two must be established in
  Member States or Associated countries, but no two
  may be established in the same Member State or
  Associated country and at least two must be
  established in international cooperation partner
  countries, but no two may be established in the
  same international cooperation partner country.
• 3. Coordination and Support actions
• For coordination and support actions the minimum
  condition is one legal entity.

11
Theme 1- HEALTH 3 Main Pillars
Biotechnology, generic tools and
technologies for human health High-throughput
research Detection, Diagnosis,
Monitoring, Therapies
Translating research for human
Health Large-scale data gathering
Brain, Development, Ageing, HIV,
Malaria, Epidemics, Cancer, Diabetes, Rare
Diseases, Chronic Diseases
Optimising the delivery of health care to
European Citizens Better use of medicines,
quality and sustainability of health
systems, Health promotion, Disease prevention
Other Actions across the Health
Theme Coordination and Support Actions,
Responding to EU Policy Needs
Main features of transition from FP6 to
FP7 Continuity broader scope less focus on
genomics emphasis on translational research
health policy driven research strongly
reinforced. New emerging epidemics, obesity,
chronic diseases, ....
12

• 1.1 High-throughput research
• SME-driven collaborative research projects for
  developing tools and technologies for
  high-throughput research
• 1.2 Detection, Diagnosis and Monitoring
• Standardisation and improvement of pre-analytical
  procedures for in vitro diagnostics
• High throughput molecular diagnostics in
  individual patients for genetic diseases with
  heterogeneous clinical presentation

13

• 1.4 Innovative therapeutic approaches and
  interventions
• Development of emerging gene therapy tools and
  technologies for clinical application
• Gene Therapy tools targeting the central nervous
  system
• Stem cell lines for cell-based therapies.
• Development of stem cell culture conditions.
• Stem cells for kidney regeneration.
• Adding value to EU stem cell therapy research
  scientific communication and future perspectives.

14

• 2.1.2 Systems biology
• Multidisciplinary fundamental genomics and
  molecular biology approaches to study basic
  biological processes relevant to health and
  diseases
• Coordination and Support Actions in large-scale
  data gathering and systems biology
• Traditional Chinese Medicine in post-genomic era.
  (SICA Targeted region China)

15

• 2.2.1 Brain and related diseases
• Restorative approaches for therapy of
  neurodegenerative diseases.
• From mood disorders to experimental models.
• Neuronal mechanisms of vision and related
  diseases.
• Childhood and adolescent mental disorders. (SICA,
  Target regions Eastern Europe and Central Asia
  and Western Balkans)

16

• 2.3.1 Anti-microbial drug resistance including
  fungal pathogens
• Novel targets for drugs against Gram negative
  bacteria.
• Host-pathogen interactions in infections by
  Streptococcus pneumoniae.
• An integrated platform for development and
  clinical evaluation of point-of-care diagnostic
  devices for microbial detection, antibiotic
  susceptibility determination and biomarkers
• Molecular epidemiology to control nosocomial and
  community spreading of highly virulent multi-drug
  resistant strains of bacterial pathogens.
• Health and economic cost of antimicrobial
  resistance.
• Conference on genetic and biochemical tools for
  postgenomic physiological analysis of
  Staphylococcus, in particular MRSA.

17

• 2.3.2 HIV, AIDS, malaria and tuberculosis
• Network on HIV and anti-HIV drug resistance
• HIV and Hepatitis co-infection
• Blocking the transmission of malaria the
  mosquito vector target.
• European network for study and clinical
  management of TB drug resistance.
• Support platform for the development of PRD
  vaccines
• Highly innovative research in HIV/AIDS, malaria
  and tuberculosis between Indian and European
  partners. (SICA, Targeted Region India)
• Coordination of European research activities with
  global initiatives, including Public-Private-Partn
  erships (SICA Targeted Regions ICPC).
• Next generation of researchers for HIV/AIDS,
  malaria, tuberculosis and neglected infectious
  diseases (SICA Targeted Regions ICPC).

18

• 2.3.3 Potentially new and re-emerging epidemics
• Strengthening research on prediction,
  identification, modelling and surveillance of
  newly emerging infectious diseases in humans.
• Definition of research needs and priorities in
  Europe in the area of Emerging Infectious
  Epidemics.

19

• 2.3.4 Neglected infectious diseases
• Development of new tools to control infections
  due to parasites of the Trypanosomatidae family
  (SICA, Target Regions ICPC)
• Development of a Leishmania vaccine (SICA, Target
  Regions ICPC)
• Bioprospecting for drug leads (SICA, Target
  Regions ICPC)

20

• 2.4.1 Cancer
• Innovative combination clinical trials for
  multimodal cancer therapy.
• Role of inflammation in tumour initiation and
  progression.
• Epidemiology of gene-environment interactions
  involved in carcinogenesis.
• Translating the hypoxic tumour microenvironment.
• ERA-NET on optimisation of the use of cancer
  registries for cancer research purposes
• Studying cancer aetiology in Latin America.
  (SICA, Target Regions Latin America)

21

• 2.4.2 Cardiovascular Disease (CVD)
• Congenital pathologies affecting the heart.
• Cell therapies for the treatment of heart
  ischemia.
• Organ imaging in CVD.
• Integrating pharmacogenomic approaches into the
  treatment of CVD.

22

• 2.4.3 Diabetes and Obesity
• Nutritional signals and the development of new
  diabetes/obesity therapeutic agents.
• Markers and treatment for diabetic neuropathy
  complications.
• Geno- and phenotypical differentiation of type 2
  subjects and monogenic subjects.
• Use of beta cell imaging in diabetes mellitus.

23

• 2.4.5 Other Chronic Diseases
• Understanding and combating age-related muscle
  weakness.
• Translational research aiming for a treatment of
  urinary incontinence.
• Early processes in the pathogenesis of chronic
  inflammatory diseases.

24

• 3.1 Translating clinical research into clinical
  practice including better use of
• medicines, and appropriate use of behavioural and
  organisational
• interventions and health therapies and
  technologies
• Implementation of research into healthcare
  practice
• Self-medication and patient safety
• Patient Safety Research Network
• Improving clinical decision making
• Better use of medicines.
• Continuity of clinical care.
• Patient self-management of chronic disease.
• 3.2 Quality, solidarity and sustainability of
  health systems
• Evaluation of disease management programmes
• Health systems and long term care of the elderly

25

• 3.3 Enhanced health promotion and disease
  prevention
• Promoting healthy behaviour in children and
  adolescents
• Interventions addressing the gradient of health
  inequalities
• Public health interventions addressing the abuse
  of alcohol.
• Evaluation of suicide prevention strategies
  across and within European countries.
• Improve vaccination coverage
• 3.4 Horizontal Coordination and Support Actions
  across Optimising the Delivery of Health Care to
  European Citizens
• Disease networks of centres of reference.
• Effectiveness of health investments.
• Patient mobility and access to information.
• Brokering research into policy.
• A road-map for ageing research.
• Health Services Research conference
• Mental health research conference.

26

• 3.5 Specific International Cooperation Actions
  for Health System Research
• Epidemiological investigations into long-term
  trends of population health as consequence of
  socio-economic transitions, including life-style
  induced health problems. SICA (Mediterranean
  Partner countries, Russia, Eastern European and
  Central Asia)
• Universal and equitable access to health care and
  health financing. SICA (MCP, ACP, Asia and Latin
  America)
• Health care intervention research optimising
  hospital care. SICA (Western Balkans)
• Health care intervention research improving
  pre-natal and maternal care. SICA (ACP and
  Mediterranean Partner Countries)

27

• 4.1 Coordination and Support Actions across the
  Theme
• Promotion and facilitation of international
  cooperation in areas relevant to the objectives
  of this theme. (SICA, ICPC)
• 4.2 Responding to EU policy needs
• Adapting off-patent medicine to the specific
  needs of paediatric populations
• Relative safety of non-steroidal
  anti-inflammatory drugs
• Effectiveness of fiscal policies for tobacco
  control in Europe

28
FP7 first calls for the Health theme

• New rules for FP7
• page number limitation for proposals
• new provisions for ethics
• ceilings for EU contribution
• Specificities of Health theme
• one-step submission
• no Networks of Excellence

29
Funding levels in the Health theme

• Maximum (and minimum) funding levels for funding
  schemes (numbers are requested EC contribution,
  not total project costs!)
• min. max.
• Small- or medium-scale focussed research
  project 3m
• Large-scale integrating project 6m 12m
• Coordination action
• Support action
• ERA-Net (for cancer topic) 2m
  
• except where otherwise stated in work
  programme.
• Warning this is an eligibility criteria !

30
Ethical framework in FP7

• Same as for FP6
• with a review foreseen for 2nd phase of FP7
  (2010-2013)
• 3 areas are excluded from funding
• Human reproductive cloning
• Intentional germ line modification ( Research
  relating to cancer of the gonads can be financed)
• Creation of human embryos for research or stem
  cell procurement (including by means of somatic
  cell nuclear transfer)
• new for FP7
• All the information on ethics must be included
  in the proposalThe EC services dealing with the
  ethical review will not request additional
  information from the co-ordinator after the
  evaluation.

31
Ethics in the HEALTH theme

• Key issues
• for humans Informed Consent / Data Protection /
  Privacy
• for animals the 3Rs (Reduce, Replace, Refine)
• for human embryonic stem cells, same conditions
  as in FP6

• recommendations
• When a researcher is using personal data,
  animals, human tissue or human subjects, the
  following points should be addressed
• necessity / no alternative?
• benefit / burden

32
What was funded in FP6 in the LifeSciences
priority (2003-06)
2.4 billion in research grants 604 projects in
4 years Average success rate 25.4
Total number of participants 7,426
33
Find partners for your projects
www.smesgohealth.org

www.smesgohealth.org
34
Thank you for your attention!
Dr. Astrid Hoebertz FFG Austrian Research
Promotion Agency European and International
Programmes Unit for Life Sciences Email
astrid.hoebertz_at_ffg.at Phone [phone]